TORONTO and GLIL YAM, Israel

多伦多和以色列吉勒亚姆

,

，

May 7, 2026

2026年5月7日

/PRNewswire/ --

/PRNewswire/ --

IM Cannabis Corp.

IM大麻公司

('

('

IMC

IMC

' or the '

‘ 或者 ‘

Company

公司

') (Nasdaq:

') （纳斯达克：

IMCC

国际摩托车越野赛锦标赛场

), a medical cannabis company with operations in Israel and Germany, today announced the closing of a US$300,000 convertible note financing in a private placement with an institutional investor, bringing the total gross proceeds raised in recent similar financings to US$550,000.

)，一家在以色列和德国运营的医用大麻公司，今天宣布在一次与机构投资者的私人配售中完成了 30 万美元的可转换票据融资，使得近期类似融资的总毛收入达到 55 万美元。

First Note

第一张便条

Pursuant to a note purchase agreement between the Company and Lender dated April 6, 2026 (the '

根据公司与贷款人于2026年4月6日签订的票据购买协议（“

First Note Purchase Agreement

首次票据购买协议

'), the Company issued the Lender a note in the principal amount of US$250,000, with an original issuance discount of 10% (the '

“），公司向贷款人发行了本金金额为250,000美元的票据，原始发行折扣为10%（“

First Note

第一张便条

').

`').``

The First Note bears interest at a rate of 8% per annum, increasing to 14% upon the occurrence and continuation of an event of default, as defined in the First Note. The First Note is not repayable in cash and the Company's obligations thereunder will be satisfied solely through the issuance of common shares in the capital of the Company (the '.

第一期票据的年利率为8%，在发生并持续出现违约事件时（如第一期票据中所定义），利率将提高至14%。第一期票据不可用现金偿还，公司的还款义务将仅通过发行公司股本中的普通股来履行（“）。

Common Shares

普通股

') upon conversion.

`) 转换时。`

The conversion price in the First Note is set to the lower of (i) a fixed price of US$0.339 per Common Share, or (ii) 90% of the lowest daily volume-weighted average price ('

第一票据中的转换价格设定为以下两者中的较低者：(i) 每股普通股 0.339 美元的固定价格，或 (ii) 最低每日成交量加权平均价格的 90%。

VWAP

成交量加权平均价格

') during the 20 consecutive trading days preceding the conversion date, subject to a floor price of US$0.07. The First Note includes customary limitations, including a 4.99% beneficial ownership cap.

') 在转换日期前的连续20个交易日内，但受最低价格每股0.07美元的限制。第一期票据包括常规的限制条件，包括4.99%的受益所有权上限。

In connection with the First Note, the Company issued a warrant to purchase up to 272,861 Common Shares (the '

与第一张票据相关，公司发行了可购买多达272,861股普通股的认股权证（“

First Note Warrants

首次注释保证

') at an exercise price of C$0.47 per Common Share. The First Note Warrants became immediately exercisable upon its issuance date, April 6, 2026, and will expire after five years, on April 6, 2031.

`)，行权价格为每股普通股0.47加元。第一票据权证自发行日2026年4月6日起立即可行权，并于五年后，即2031年4月6日到期。`

The Company used the net proceeds from the First Note for general corporate purposes.

公司已将第一期票据的净收益用于一般公司用途。

Second Note

第二注释

Pursuant to a note purchase agreement between the Company and Lender dated May 7, 2026 (the '

根据公司与贷款人于2026年5月7日签订的票据购买协议（“

Second Note Purchase Agreement

第二份票据购买协议

'), the Company issued the Lender a note in the principal amount of US$300,000, with an original issuance discount of 10% (the '

“），公司向贷款人发行了本金金额为30万美元的票据，原始发行折扣为10%（“

Second Note

第二注释

').

`').``

The Second Note bears interest at a rate of 8% per annum, increasing to 14% upon the occurrence and continuation of an event of default. The Second Note is not repayable in cash and the Company's obligations thereunder will be satisfied solely through the issuance of Common Shares upon conversion.

第二张票据的年利率为8%，在发生违约事件且该事件持续时，利率将提高至14%。第二张票据不可用现金偿还，公司对该票据的责任将仅通过转换时发行普通股来履行。

The conversion price in the Second Note was set to the lower of (i) a fixed price of US$0.266 per Common Share, or (ii) 90% of the lowest daily VWAP during the 20 consecutive trading days preceding the conversion date, subject to a floor price of US$0.05. The Second Note includes customary limitations, including a 4.99% beneficial ownership cap..

第二票据的转换价格设定为以下两者中的较低者：(i) 每股普通股 0.266 美元的固定价格，或 (ii) 转换日期前连续 20 个交易日最低日均加权平均价格（VWAP）的 90%，但受制于 0.05 美元的底价。第二票据包含常规限制，包括 4.99% 的实益所有权上限。

In connection with the Second Note, the Company issued a warrant to purchase up to 1,127,820 Common Shares (the '

与此第二票据相关，公司发行了可购买多达1,127,820股普通股的认股权证（该...

Second Note Warrants

第二票据权证

') at an exercise price of C$0.36 per Common Share. The Second Note Warrants became exercisable immediately upon its issuance date, May, 7, 2026, and will expire after five years on May 7, 2031.

`)，行权价格为每股普通股0.36加元。第二票据权证自发行日2026年5月7日起立即可行权，并于五年后的2031年5月7日到期。`

The Company intends to use the net proceeds for general corporate purposes.

公司打算将净收益用于一般企业用途。

In connection with the First Note Purchase Agreement and Second Note Purchase Agreement, the Company has agreed to reserve sufficient Common Shares for issuance upon conversion of the First Note and Second Note, respectively, and exercise of the First Note Warrants and Second Note Warrants, respectively, and to file a resale registration statements on Form F-3 with the U.S.

根据第一票据购买协议和第二票据购买协议，公司已同意分别为第一票据和第二票据的转换以及第一票据认股权证和第二票据认股权证的行使预留足够的普通股，并向美国证券交易委员会提交一份F-3表格的转售注册声明。

Securities and Exchange Commission (the '.

证券交易委员会（“

SEC

证券交易委员会

') and to use commercially reasonable efforts to secure its effectiveness within the timeframes agreed with the Lender.

')，并尽商业上合理的努力确保其在与贷款人约定的时间框架内生效。

All securities issued under the financings described above are subject to: (i) a four month and one day hold period from the date of issuance and (ii) applicable legends as required pursuant to the U.S. Securities Act of 1933, as amended (the '

上述融资项下发行的所有证券均受以下条件限制：(i) 自发行之日起四个月零一天的持有期；及 (ii) 根据经修订的1933年《美国证券法》要求的适用条款（“

Securities Act

证券法

'). The private placements of the securities offered to the Lender were made in reliance on an exemption from (x) registration under Section 4(a)(2) of the Securities Act and (y) applicable Canadian securities laws. Accordingly, the securities issued in the private placements may not be offered or sold in the United States or Canada except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws or an exemption pursuant to Canadian securities laws..

`). 向贷款人发行的证券私募是依赖于《证券法》第4(a)(2)节规定的注册豁免及适用的加拿大证券法豁免进行的。因此，除非依据有效的注册声明、或符合《证券法》和适用的州证券法的注册要求豁免、或依据加拿大证券法的豁免，否则不得在美国或加拿大提供或出售私募中发行的证券。`

About IM Cannabis Corp.

关于IM大麻公司

IMC (Nasdaq:

IMC（纳斯达克：

IMCC

IMCC

) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors..

）是一家国际公司，专注于在全球市场构建和扩展创新业务和技术。该公司目前运营一个医疗大麻平台，为以色列和德国的患者提供服务，同时评估扩展到其他技术驱动领域的机遇。

The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain.

IMC生态系统通过其子公司在以色列开展业务，这些子公司利用多年独有的数据和患者洞察，进口并向医疗患者分发大麻。该公司还在以色列经营医用大麻零售药店和在线平台，确保IMC产品在整个价值链中的安全交付和质量控制。

In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients..

在德国，IMC生态系统通过Adjupharm GmbH运作，该公司将大麻分销到药房，用于医疗大麻患者。

Company Contact:

公司联系人：

Michal Efraty

米哈尔·埃弗拉蒂

Investor & Public Relations

投资者与公共关系

IM Cannabis Corp.

IM大麻公司

[email protected]

电子邮件地址

Oren Shuster, CEO

奥伦·舒斯特，首席执行官

IM Cannabis Corp.

IM大麻公司

[email protected]

电子邮件地址

Disclaimer for Forward-Looking Statements

前瞻性声明免责声明

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, '

本新闻稿包含适用的加拿大和美国证券法下的前瞻性信息或前瞻性陈述（统称为“

forward-looking statements

前瞻性声明

'). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'likely' and 'intend' and statements that an event or result 'may', 'will', 'should', 'could' or 'might' occur or be achieved and other similar expressions.

`). 所有涉及我们预期未来将发生的活动或发展的信息均为前瞻性陈述。前瞻性陈述通常（但并非总是）通过使用诸如“寻求”、“预期”、“相信”、“计划”、“估计”、“预计”、“可能”和“打算”等词语以及表示某事件或结果“可能”、“将”、“应该”、“可能”或“或许”发生或实现的陈述及其他类似表达来识别。`

Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the receipt of and use of proceeds from the financings and the preparation, timing and filing of registration statement with the SEC.

前瞻性声明基于管理层在声明作出之日的估计和意见。在新闻稿中，此类前瞻性声明包括但不限于与以下事项有关的声明：收到融资款项及其用途，以及准备、时间安排和向美国证券交易委员会（SEC）提交注册声明。

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks.

上述前瞻性声明和假设的列表并不详尽。由于前瞻性声明涉及未来的事件和情况，其本质存在固有的风险和不确定性。由于多种因素和风险，实际结果可能与这些前瞻性声明目前预期或暗示的结果有重大差异。

These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the '.

这些包括：公司未能遵守在高度监管行业中的适用监管要求；公司运营所在司法管辖区政府政策和法规的意外变化；公司继续满足纳斯达克资本市场上市要求的能力；任何未能保持良好状态或续期其许可证的意外情况；公司及其子公司（统称为“。

Group

群组

') to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war Israel is facing on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company's inability to take advantage of the legalization of medicinal cannabis in Germany; the Company's inability to use the proceeds as set out herein; and the Company's inability to file a registration statement in the timelines outlined here.

') 实现其销售承诺或增长目标的能力；集团依赖第三方供应协议以提供足量的医用大麻来履行其义务；集团可能面临的责任风险、与此相关的感知风险水平，以及涉及集团的任何诉讼或其他类似纠纷或法律程序的预期结果；竞争加剧的影响；缺乏并购机会；不利的市场条件；生产数量、质量和成本估算固有的不确定性以及潜在的意外成本和费用的风险；因使用集团的大麻产品而产生的产品责任和其他安全相关责任风险；供应链限制；对关键人员的依赖；现有债务违约的风险；围绕东欧和中东地区战争、冲突和动乱的风险，包括以色列面临的多线战争对公司、其运营以及以色列医用大麻行业的影响；公司专注于以色列和德国市场的相关风险；公司无法实现可持续盈利和/或提升股东价值；公司无法积极管理成本和/或改善利润率；公司无法增长和/或维持销售；公司无法实现其目标和/或战略计划；公司无法降低成本和/或维持收入；公司无法利用德国医用大麻合法化的机会；公司无法按此处所述使用所得款项；以及公司无法在规定的时间表内提交注册声明。

Please see the other risks, uncertainties and factors set out under the heading 'Risk Factors' in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at

请参阅公司截至2025年12月31日的年度报告中“风险因素”标题下列出的其他风险、不确定性和因素，该报告可在SEDAR+上的公司发行人档案中查阅。

www.sedarplus.ca

www.sedarplus.ca

and Edgar at

和埃德加在

www.sec.gov/edgar

www.sec.gov/edgar

. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws.

本新闻稿中包含的任何前瞻性声明均自本新闻稿发布之日起作出，并基于管理层在作出此类前瞻性信息时的信念、估计、预期和意见。公司不承担更新前瞻性声明的义务，除非适用的证券法要求。

Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement..

投资者不应过分依赖前瞻性陈述。本新闻稿中包含的前瞻性陈述受此警示声明明确限定。

Logo -

标志 -

https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

SOURCE IM Cannabis Corp

资料来源：IM Cannabis Corp

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示